The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

COMy 2019 | Daratumumab practical considerations in MM

Name: Daratumumab practical considerations in MM
Uploaded: 2019-05-16T00:00:00.000Z
Duration: 3 min 36 s
Description: Torben Plesner, MD, University of Southern Denmark, Odense, Denmark, shares practical considerations when using anti-CD38 antibodies, gained from his long experience of treating multiple myeloma with daratumumab. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

Torben Plesner • 16 May 2019

COMy 2019

Multiple Myeloma Daratumumab Dexamethasone Lenalidomide

Torben Plesner, MD, University of Southern Denmark, Odense, Denmark, shares practical considerations when using anti-CD38 antibodies, gained from his long experience of treating multiple myeloma with daratumumab. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.